Research Compendium/Wolverine Stack
Stacks & FormulasResearch OnlyNot For Human Consumption

Wolverine Stack

TB-500 + BPC-157 Hybrid · Wolverine Recovery Stack

The most popular recovery combination, BPC-157 and TB-500 together in one pen or vial, covering both local and whole-body repair.

MECHANISM OF ACTION

The Wolverine Stack puts BPC-157 and TB-500 together in a single formulation so you get both working at the same time. BPC-157 handles the local work: growing new blood vessels into the injury site, protecting the gut lining, and kicking off repair in tendons and ligaments. TB-500 adds broader coverage: it sends repair signals throughout the body, calls in specialised repair cells, and damps down inflammation system-wide. The idea is that BPC-157's local vascular repair and TB-500's body-wide cell migration create a more complete recovery environment together than either does alone. Available in vial, pen, and nasal spray formats.

RESEARCH APPLICATIONS

  • Comprehensive tendon, ligament, and muscle injury recovery
  • Post-surgical tissue repair research
  • Systemic + local recovery model (TB-500 systemic + BPC-157 local)
  • GI repair with systemic anti-inflammatory support
  • Athletic recovery and soft tissue research

RESEARCH HIGHLIGHTS

Synergistic Mechanism Evidence

Independent studies on each component show complementary mechanisms - TB-500 mobilises progenitor cells systemically while BPC-157 creates the angiogenic scaffold for integration at the injury site.

Ref: Multiple preclinical studies (see BPC-157 and TB-500 individual pages)

RESEARCH PROTOCOL NOTES

Typical blend ratioBPC-157 : TB-500 - 1:1 to 1:2 by weight in most commercial formats
Available formatsVial (5–20mg), Pen (Wolverine Hybrid Pen - Noventra, iPharma, BodyPharm, VMed Nasal Spray)
Research advantageCombined vial avoids two separate reconstitutions; co-administration timing no longer a variable

Chemical Identity

Storage & Stability

-20°C lyophilised. Reconstituted: 2–8°C, 21 days. Same storage rules as component peptides - the blend does not reduce stability.

Regulatory Status

Combined research compound. Same regulatory status as each component. Not WADA listed individually; TB-500 (Tβ4) is WADA S2 prohibited.